Invatec nets CE Mark for PTCA balloon catheter
Invatec, a developer of interventional products, has received a CE Mark for the In.Pact Falcon paclitaxel-eluting percutaneous transluminal coronary angioplasty (PTCA) balloon catheter, which was designed to treat atherosclerosis in the coronary arteries.
The Bethlehem, Pa.-based company said its In.Pact Falcon features FreePac, a proprietary, natural coating that separates paclitaxel molecules, facilitating their absorption into the wall of the artery. The FreePac coating was developed in collaboration with Ulrich Speck, PhD, from the department of radiology at Charite Berlin in Berlin and Bruno Scheller, MD, from the department of internal medicine at University Hospital in Homburg/Saar, Germany.
The Bethlehem, Pa.-based company said its In.Pact Falcon features FreePac, a proprietary, natural coating that separates paclitaxel molecules, facilitating their absorption into the wall of the artery. The FreePac coating was developed in collaboration with Ulrich Speck, PhD, from the department of radiology at Charite Berlin in Berlin and Bruno Scheller, MD, from the department of internal medicine at University Hospital in Homburg/Saar, Germany.